Shattuck Labs’ stock surged nearly 5% after J.P. Morgan analyst Brian Cheng upgraded the biotech firm to “overweight” with a $10 price target—potentially a 35% upside—driven by strong early data on its inflammatory bowel disease drug SL-325, poised to enter Phase Two trials this quarter.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
